Opendata, web and dolomites

NPsVLCD SIGNED

Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NPsVLCD project word cloud

Explore the words cloud of the NPsVLCD project. It provides you a very rough idea of what is the project "NPsVLCD" about.

action    leishmaniasis    trials    compliance    drugs    bioactivity    therapies    cd    series    parasitologist    despite    worldwide    amphotericin    prominent    compounds    visceral    parasitic    suffer    million    critically    compound    investment    efficiency    track    malaria    additionally    chemistry    informing    families       couple    expert    few    time    collaborations    disease    dogma    natural    dynamic    largely    severe    read    strategies    therapeutic    candidates    ignored    people    pharmacophore    progressed    patient    modular    alkaloid    leads    12    mode    progress    multidisciplinary    evaluation    resistance    urgently    concise    tempone    synthetic    kevin    affe    pharmacokinetic    modification    pharmacologist    limitations    central    structurally    contrast    synthesis    potentially    examples    leishmaniases    record    overarching    clinical    preclinical    frontline    limited    refinement    treatments    parasite    accessibility    modes    feedback    vl    andre    convergent    antiparasitic    identification    chagas    exploration    prof    thereby    pharmacophores    dependent    made    artemisinin   

Project "NPsVLCD" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD 

Organization address
address: WELLINGTON SQUARE UNIVERSITY OFFICES
city: OXFORD
postcode: OX1 2JD
website: www.ox.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 212˙933 €
 EC max contribution 212˙933 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) coordinator 212˙933.00

Map

 Project objective

The development of new therapies for leishmaniases (which affeThe development of new therapies for visceral leishmaniasis (affects ~12 million people worldwide) and Chagas disease (~6-7 million people worldwide) is critically dependent on the identification of novel pharmacophores with new modes of action. Current treatments suffer from severe side effects, high cost, patient compliance issues, and emerging resistance; as such, new therapeutic leads are urgently required. Despite significant investment, limited progress has been made with research into new 'synthetic' drugs: no candidates are in clinical trials (although two compounds have recently progressed to preclinical evaluation for VL). In contrast, research into natural product-derived drugs has been largely ignored, despite their track record as frontline treatments for VL (amphotericin B) and the most prominent parasitic disease, malaria (artemisinin). In this project, we challenge this dogma through the exploration of a series of structurally-related alkaloid natural product families, where highly promising antiparasitic bioactivity has been observed in the few examples studied. The selection of these families is additionally based on their accessibility through concise, modular and convergent synthetic strategies, which facilitate modification. We couple this central focus of synthetic chemistry with collaborations to evaluate bioactivity (with expert parasitologist Prof Andre Tempone), and identify pharmacokinetic/dynamic limitations (with expert pharmacologist Prof Kevin Read), thereby informing analogue refinement and synthesis. This multidisciplinary approach will greatly enhance the impact of the synthetic chemistry work by providing 'real-time' feedback into compound design, enhancing project efficiency and progress. Our overarching, long term impact objective is to identify a new pharmacophore (and potentially new parasite target / mode of action) for the potential development of VL/CD therapies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NPSVLCD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NPSVLCD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

VITAL-ISE (2020)

Development and application of ion-sensors for multi-analyte detection

Read More  

BirthControlEnvirons (2019)

Contraception meets the environment: everyday contraceptive practices, politics, and futures in a toxic age

Read More  

ROSETTA (2020)

Deciphering the Role of aberrant glycOSylation in the rEsponse to Targeted TherApies for breast cancer

Read More